

I26 documenti

search details

cassader m[Author] OR (gambino r[Author] AND cassader m[Author] AND gambino r[Author]) AND ("2016/01/01"[PDAT] : "2019/12/31"[PDAT])

1: Gambino R, Fanni G, Togliatto G, Ponzo V, Goitre I, Cassader M, Brizzi MF, Bo S. Rs12778366 single nucleotide polymorphism of Sirtuin 1 (SIRT1) and response to resveratrol supplementation in patients with type 2 diabetes mellitus. *Acta Diabetol.* 2019 Aug;56(8):963–966. doi: 10.1007/s00592-019-01341-6. Epub 2019 Apr  
12. PubMed PMID: 30980188.

2: Musso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. *BMJ.* 2019 Apr 9;365:l1328. doi: 10.1136/bmj.l1328. PubMed PMID: 30967375; PubMed Central PMCID: PMC6454301.

3: Musso G, Saba F, Cassader M, Paschetta E, De Michieli F, Pinach S, Framarin L, Berrutti M, Leone N, Parente R, Ayoubi Khajekini MT, Zarovska A, Gambino R. Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation. *Am J Gastroenterol.* 2019 Apr;114(4):607–619. doi: 10.14309/ajg.000000000000154. PubMed PMID: 30920415.

4: Bo S, Gambino R, Ponzo V, Cioffi I, Goitre I, Evangelista A, Ciccone G, Cassader M, Procopio M. Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial. *Nutr Diabetes.* 2018 Sep 20;8(1):51. doi: 10.1038/s41387-018-0059-4. PubMed PMID: 30237505; PubMed Central PMCID: PMC6147949.

5: Ferrocino I, Ponzo V, Gambino R, Zarovska A, Leone F, Monzeglio C, Goitre I,

Rosato R, Romano A, Grassi G, Broglio F, Cassader M, Cocolin L, Bo S. Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM). *Sci Rep.* 2018 Aug 15;8(1):12216. doi: 10.1038/s41598-018-30735-9. PubMed PMID: 30111822; PubMed Central PMCID: PMC6093919.

6: Musso G, Cassader M, Paschetta E, Gambino R. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. *Gastroenterology.* 2018 Aug;155(2):282-302.e8. doi: 10.1053/j.gastro.2018.06.031. Epub 2018 Jun 12. Review. PubMed PMID: 29906416.

7: Ponzio V, Gentile L, Gambino R, Rosato R, Cioffi I, Pellegrini N, Benso A, Broglio F, Cassader M, Bo S. Incidence of diabetes mellitus, cardiovascular outcomes and mortality after a 12-month lifestyle intervention: A 9-year follow-up. *Diabetes Metab.* 2018 Nov;44(5):449-451. doi: 10.1016/j.diabet.2018.04.008. Epub 2018 May 8. PubMed PMID: 29773350.

8: Musso G, Gambino R, Cassader M, Paschetta E, Sircana A. Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution. *Trends Pharmacol Sci.* 2018 Apr;39(4):387-401. doi: 10.1016/j.tips.2018.01.003. Epub 2018 Feb 27. Review. PubMed PMID: 29499974.

9: Bo S, Togliatto G, Gambino R, Ponzio V, Lombardo G, Rosato R, Cassader M, Brizzi MF. Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation. *Acta Diabetol.* 2018 Apr;55(4):331-340. doi: 10.1007/s00592-017-1097-4. Epub 2018 Jan 12. PubMed PMID: 29330620; PubMed Central PMCID: PMC5851693.

10: Musso G, Cassader M, Gambino R. Letter by Musso et al Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of

Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".  
Circulation. 2017 Oct 17;136(16):1563–1564. doi:  
10.1161/CIRCULATIONAHA.117.028217. PubMed PMID: 29038211.

11: Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, Della Latta V, Ciociaro D, Abate ML, Gambino R, Cassader M, Bugianesi E, Gastaldelli A. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. Hepatology. 2018 Jan;67(1):145–158. doi: 10.1002/hep.29465. Epub 2017 Nov 17. PubMed PMID: 28802074.

12: Musso G, Cassader M, De Michieli F, Paschetta E, Pinach S, Saba F, Bongiovanni D, Framarin L, Berrutti M, Leone N, Corvisieri S, Parente R, Molinaro F, Sircana A, Bo S, Gambino R. MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat. Hum Mol Genet. 2017 May 1;26(9):1785. doi: 10.1093/hmg/ddx126. PubMed PMID: 28398481.

13: Musso G, Cassader M, De Michieli F, Paschetta E, Pinach S, Saba F, Bongiovanni D, Framarin L, Berrutti M, Leone N, Corvisieri S, Parente R, Molinaro F, Sircana A, Bo S, Gambino R. MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat. Hum Mol Genet. 2017 May 1;26(9):1747–1758. doi: 10.1093/hmg/ddw400. Erratum in: Hum Mol Genet. 2017 May 1;26(9):1785. PubMed PMID: 28334911.

14: Bo S, Seletto M, Choc A, Ponzo V, Lezo A, Demagistris A, Evangelista A, Ciccone G, Bertolino M, Cassader M, Gambino R. The acute impact of the intake of four types of bread on satiety and blood concentrations of glucose, insulin, free fatty acids, triglyceride and acylated ghrelin. A randomized controlled cross-over trial. Food Res Int. 2017 Feb;92:40–47. doi:

10.1016/j.foodres.2016.12.019. Epub 2016 Dec 27. PubMed PMID: 28290296.

15: Musso G, Cipolla U, Cassader M, Pinach S, Saba F, De Michieli F, Paschetta E, Bongiovanni D, Framarin L, Leone N, Berrutti M, Rosina F, Corvisieri S, Molinaro F, Sircana A, Gambino R. TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. *J Lipid Res.* 2017 Jun;58(6):1221–1229. doi: 10.1194/jlr.M075028. Epub 2017 Feb 27. PubMed PMID: 28242789; PubMed Central PMCID: PMC5454511.

16: Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. *JAMA Intern Med.* 2017 May 1;177(5):633–640. doi: 10.1001/jamainternmed.2016.9607. Erratum in: *JAMA Intern Med.* 2017 May 1;177(5):747. PubMed PMID: 28241279; PubMed Central PMCID: PMC5470366.

17: Bo S, Ponzo V, Evangelista A, Ciccone G, Goitre I, Saba F, Procopio M, Cassader M, Gambino R. Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial. *Acta Diabetol.* 2017 May;54(5):499–507. doi: 10.1007/s00592-017-0977-y. Epub 2017 Feb 25. PubMed PMID: 28238190.

18: Musso G, Cassader M, Paschetta E, Gambino R. Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges. *Hepatology.* 2017 Mar;65(3):1058–1061. doi: 10.1002/hep.28960. Epub 2017 Jan 31. PubMed PMID: 27880988.

19: Musso G, Cassader M, Cohny S, De Michieli F, Pinach S, Saba F, Gambino R. Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. *Diabetes Care.* 2016 Oct;39(10):1830–45. doi: 10.2337/dc15-1182. Review. PubMed PMID: 27660122.

20: Musso G, De Michieli F, Bongiovanni D, Parente R, Framarin L, Leone N, Berrutti M, Gambino R, Cassader M, Cohn S, Paschetta E. New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease. *Clin Gastroenterol Hepatol*. 2017 Jul;15(7):972-985. doi: 10.1016/j.cgh.2016.08.002. Epub 2016 Aug 10. Review. PubMed PMID: 27521506.

21: Bo S, Ponzo V, Ciccone G, Evangelista A, Saba F, Goitre I, Procopio M, Pagano GF, Cassader M, Gambino R. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. *Pharmacol Res*. 2016 Sep;111:896-905. doi: 10.1016/j.phrs.2016.08.010. Epub 2016 Aug 9. PubMed PMID: 27520400.

22: Bo S, Ponzo V, Goitre I, Fadda M, Pezzana A, Beccuti G, Gambino R, Cassader M, Soldati L, Broglio F. Predictive role of the Mediterranean diet on mortality in individuals at low cardiovascular risk: a 12-year follow-up population-based cohort study. *J Transl Med*. 2016 Apr 12;14:91. doi: 10.1186/s12967-016-0851-7. PubMed PMID: 27071746; PubMed Central PMCID: PMC4830057.

23: Gambino R, Bugianesi E, Rosso C, Mezzabotta L, Pinach S, Alemanno N, Saba F, Cassader M. Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load. *Int J Mol Sci*. 2016 Mar 31;17(4):479. doi: 10.3390/ijms17040479. PubMed PMID: 27043543; PubMed Central PMCID: PMC4848935.

24: Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. *Nat Rev Drug Discov*. 2016 Apr;15(4):249-74. doi: 10.1038/nrd.2015.3. Epub 2016 Jan 22. Review. PubMed PMID: 26794269.

25: Musso G, Cassader M, Paschetta E, Gambino R. TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD. *J Hepatol.* 2016 Apr;64(4):979–81. doi: 10.1016/j.jhep.2015.11.036. Epub 2015 Dec 8. PubMed PMID: 26673224.

26: Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A, Saba F, Vanni E, Younes R, Saponaro C, Buzzigoli E, Caviglia GP, Abate ML, Smedile A, Rizzetto M, Cassader M, Gastaldelli A, Bugianesi E. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. *Hepatology.* 2016 Jan;63(1):107–16. doi: 10.1002/hep.28287. Epub 2015 Dec 8. Erratum in: *Hepatology.* 2017 Sep;66(3):1011. PubMed PMID: 26473614.